In this book, well-known physicians, Bocker, Eckardt and Breithardt
have put together a succinct and focused book that compliments the
CATA Series well. Implantation of defibrillators has evolved
dramatically since its introduction by Mirowski in 1980.
Technological improvements in devices and leads included a gradual
reduction in the size of the device, the introduction of the
endocardial approach in 1988, the biphasic waveform and
antitachycardia pacing in 1991, pectoral implantation in 1995,
inclusion of DDD pacing in 1996 and the delivery of atrial
therapies in 1998.
Since the first implantation, a huge body of information on the
impact of implantable cardioverter defibrillators (ICD) on
prognosis has become available, first as observational studies and
later as prospective randomized trials. At the present time, there
is a large evidence base from the several ICD trials, although it
was not always certain that such a large body of ICD evidence would
accumulate.
विषयसूची
Introduction. 4.
Evolution of guidelines for defibrillator therapy. 5.
Format of guidelines. 6.
Background of ICD therapy. 7.
Aims of ICD therapy. 7.
Clinical efficacy of ICD therapy. 8.
Alternatives to ICD therapy. 8.
Comparison of drugs and devices. 10.
Current indications for ICD therapy. 11.
Contraindications to ICD therapy. 11.
ICD therapy in specific disease states. 12.
CAD. 12.
Risk stratification. 13.
Secondary prevention of cardiac arrest or sustained ventricular
tachycardias in patients with coronary artery disease. 17.
Primary prevention of sudden cardiac death after myocardial
infarction. 23.
DCM… 26.
Secondary prevention of cardiac arrest or sustained ventricular
tachycardias in nonischemic dilated cardiomyopathy. 26.
Primary prevention of sudden cardiac death. 27.
Brugada syndrome. 33.
Secondary prevention of cardiac arrest in patients with Brugada
syndrome. 34.
Primary prevention of sudden death in patients with the Brugada
ECG pattern. 35.
Hypertrophic cardiomyopathy. 37.
Secondary prevention of cardiac arrest or sustained ventricular
tachycardias. 38.
Primary prevention of sudden death in HCM… 39.
Long QT syndrome. 43.
Results of ICD therapy in patients with the long QT syndrome.
46.
Short QT Syndrome. 47.
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 48.
Catecholamine- or exercise induced polymorphic ventricular
tachycardia. 51.
Other patients believed at high risk. 52.
Defibrillators as a bridge to heart transplantation. 52.
Cardiac Resynchronization Therapy (CRT) 53.
Legal implications of defibrillator guidelines. 56.
Literature. 64
लेखक के बारे में
Author: Dirk Böcker, MD, Lars Eckardt, MD, Günter
Breithardt, MD, FESC, FACC – University Hospital, Department of
Cardiology and Angiology, Münster, Germany
Editor: A. John Camm